Advanced search    

Search: authors:"Peter C. Taylor"

17 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach

Merck Sharp & Dohme Corp., and honoraria from Merck for participation in a modified Delphi panel. Finbar O’Shea is an employee of St. James’s Hospital, Dublin, Ireland. Peter C Taylor has received grants ... , Pfizer, and Sandoz. He has received honoraria from Merck for participation in a modified Delphi panel. Peter C Taylor is an employee of the University of Oxford. Gavin Dickie is an employee of Adelphi

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

Institut Pierre Louis d'Epidémiologie et de Santé Publique , Sorbonne Universités, UPMC Universitaire Paris 06, Paris , France 3 Peter C. Taylor 4 Botnar Research Centre, NDORMS, University of Oxford ... , Lilly, AbbVie and Novartis, and consultancy fees from Lilly, Novartis and Janssen. Peter C. Taylor has received research grants from UCB, Lilly, Janssen and Celgene, and consultancy fees from Roche, UCB

A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford , Oxford , UK 1 Peter C. Taylor 2 Present Address: ICE Creates Ltd , Birkenhead , UK 3 Global Health & Value-GIP , Pfizer, Rome

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Objectives To investigate the safety of ofatumumab retreatment in rheumatoid arthritis. Methods Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the...

Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting

Objectives To determine the repeatability and response to therapy of dynamic contrast-enhanced (DCE) MRI biomarkers of synovitis in the hand and wrist of rheumatoid arthritis (RA) patients, and in particular the performance of the transfer constant K trans , in a multicentre trial setting. Methods DCE-MRI and RA MRI scoring (RAMRIS) were performed with meticulous standardisation...

Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study

Objective To determine if variations in trial eligibility criteria and patient baseline characteristics could be considered effect modifiers of the treatment response when testing targeted therapies (biological agents and targeted synthetic disease modifying antirheumatic drugs (DMARDs)) for rheumatoid arthritis (RA). Methods We conducted a meta-epidemiological study of all...

Early Metacarpal Bone Mineral Density Loss Using Digital X-Ray Radiogrammetry and 3-Tesla Wrist MRI in Established Rheumatoid Arthritis: A Longitudinal One-Year Observational Study

, Joseph V. Hajnal, and Peter C. Taylor declare that there is no conflict of interests regarding the publication of this paper. Acknowledgments Radiograph analysis using DXR-online was done by SECTRA as an ... academic collaboration. The authors would like to thank the study MRI radiographer, Ms. Emer Hughes, research nurse consultant, Ms. Catherine McClinton, and administrator Ms. Annette Winter. Peter C. Taylor

Erratum to: A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis

, Oxford OX3 7LD, UK 2Roche Diagnostics, Ltd., Forrenstraße, 6343 Rotkreuz, Switzerland Received 6 November 2011; Accepted 20 November 2011 Copyright © 2012 Peter C. Taylor et al. This is an open access

Raised circulating tenascin-C in rheumatoid arthritis

Introduction The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TNC) are elevated in musculoskeletal disorders including rheumatoid arthritis (RA) and to assess in RA whether levels are related to clinical disease status and/or patient response to treatment. Methods TNC in serum or plasma was quantified by ELISA...

T1-Weighted Sodium MRI of the Articulator Cartilage in Osteoarthritis: A Cross Sectional and Longitudinal Study

Structural magnetic resonance imaging (MRI) has shown great utility in diagnosing soft tissue burden in osteoarthritis (OA), though MRI measures of cartilage integrity have proven more elusive. Sodium MRI can reflect the proteoglycan content of cartilage; however, it requires specialized hardware, acquisition sequences, and long imaging times. This study was designed to assess...

The value of sensitive imaging modalities in rheumatoid arthritis

clinical trial size and duration, and may permit better informed management decisions in a bid to optimally suppress synovitis and improve treatment Correspondence Peter C Taylor, Senior Lecturer and

VEGF and imaging of vessels in rheumatoid arthritis

Peter C Taylor 0 1 0 department website: 1 The Kennedy Institute Division, Imperial College School of Medicine , London , UK Chapter summary Angiogenesis is a prominent feature of

Implications of Isoniazid Resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for Immunotherapy in Bladder Cancer

We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for...

Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis

Background Disease activity measurement is a key component of rheumatoid arthritis (RA) management. Biomarkers that capture the complex and heterogeneous biology of RA have the potential to complement clinical disease activity assessment. Objectives To develop a multi-biomarker disease activity (MBDA) test for rheumatoid arthritis. Methods Candidate serum protein biomarkers were...

Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study

Dooley Constantino Pitzalis Peter C Taylor 0 0 Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Windmill Road

Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis

Antibodies against citrullinated proteins are highly specific for rheumatoid arthritis (RA), but little is understood about their citrullinated target antigens. We have detected a candidate citrullinated protein by immunoblotting lysates of monocytic and granulocytic HL-60 cells treated with peptidylarginine deiminase. In an initial screen of serum samples from four patients with...

The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis

might result from combining anti-CD4 mAbs with other biologic therapeutics [1,7,8]. Ravinder N Maini, Peter C Taylor, Ewa Paleolog, Peter Charles, Sundeept Ballara, Fionula Brennan, and Marc Feldmann